The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension
Open accessAbstract
Pulmonary arterial hypertension (PAH) is a deadly disease with no cure. Alternate conversion of angiotensin II (AngII) to angiotensin-(1–7) (Ang-(1–7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1) activation improves rodent models of PAH. Effects of recombinant human (rh) ACE2 in human PAH are unknown. Our objective was to determine the effects of rhACE2 in PAH. We defined the molecular effects of Mas1 activation using porcine pulmonary arteries, measured AngII/Ang-(1–7) levels in human PAH and conducted a phase IIa, open-label pilot study of a single infusion of rhACE2 (GSK2586881, 0.2 or 0.4 mg·kg−1 intravenously). Superoxide dismutase 2 (SOD2) and inflammatory gene expression were identified as markers of Mas1 activation. After confirming reduced plasma ACE2 activity in human PAH, five patients were enrolled in the trial. GSK2586881 was well tolerated with significant improvement in cardiac output and pulmonary vascular resistance. GSK2586881 infusion was associated with reduced plasma markers of inflammation within 2–4 h and increased SOD2 plasma protein at 2 weeks. PAH is characterised by reduced ACE2 activity. Augmentation of ACE2 in a pilot study was well tolerated, associated with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators. Targeting this pathway may be beneficial in human PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationChristman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,187
Self-citationDysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension
de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., François, C., Schalij, I., Dorfmüller, P., Simonneau, G., Fadel, E., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0411oc · Cited by 346
Cited by
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Overview of lethal human coronaviruses
Chen, B., Tian, E.-K., He, B., Tian, L., Han, R., Wang, S., Xiang, Q., Zhang, S., El Arnaout, T., & Cheng, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0190-2 · Cited by 300
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
Zipeto, D., Palmeira, J. D. F., Argañaraz, G. A., & Argañaraz, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576745 · Cited by 267
Metadata
- Authors
- Hemnes, A. R., Rathinasabapathy, A., Austin, E. A., Brittain, E. L., Carrier, E. J., Chen, X., Fessel, J. P., Fike, C. D., Fong, P., Fortune, N., Gerszten, R. E., Johnson, J. A., Kaplowitz, M., Newman, J. H., Piana, R., Pugh, M. E., Rice, T. W., Robbins, I. M., Wheeler, L., Yu, C., Loyd, J. E., & West, J.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2018-06
- Volume
- 51
- Issue
- 6
- Pages
- 1702638
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2808672927
- Cited by
- 220
- References
- 4
- FWCI
- 23.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1183/13993003.02638-2017
- The paper
- Hemnes, A. R., Rathinasabapathy, A., Austin, E. A., Brittain, E. L., Carrier, E. J., Chen, X., Fessel, J. P., Fike, C. D., Fong, P., Fortune, N., Gerszten, R. E., Johnson, J. A., Kaplowitz, M., Newman, J. H., Piana, R., Pugh, M. E., Rice, T. W., Robbins, I. M., Wheeler, L., . . . West, J. (2018). A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal. https://doi.org/10.1183/13993003.02638-2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.